Please ensure Javascript is enabled for purposes of website accessibility

Can Keytruda Return Merck & Co. to Growth?

By Cory Renauer – Oct 28, 2016 at 9:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A speedy approval pushed the underdog into the front of the line for lung cancer patients, but another rival is snapping at its heels.

Merck & Co. Logo Keytruda Lung Cancer

Image source: Merck & Co.

Following a speedy FDA approval, Keytruda from Merck & Co. (MRK 0.95%) became the first drug in its class to reach the front line in lung cancer. Until recently, it seemed Bristol-Myers Squibb (BMY 0.03%) would dominate this important field with Opdivo, but surprisingly poor trial results set it back a few paces.

This is great news for Merck investors who have watched the company's sales slide for years, but the cheering might not last very long. Roche (RHHBY 0.99%) isn't far behind, with a similar drug threatening to pour water on Keytruda's latest advantage before it catches fire.

MRK Revenue (TTM) Chart

MRK Revenue (TTM) data by YCharts.

Total revenue at Merck has fallen a great deal over the past several years. Let's have a closer look at Keytruda's playing field to see if its recent victory can return the big American pharma to growth.

Christmas in October

It was early September when the FDA accepted Keytruda's application for first-line treatment of lung cancer patients whose tumors express high levels of PD-L1 on their surface. Although the agency set an action date on Christmas Eve, it gave Merck a thumbs-up just seven weeks after accepting the application. 

Merck's Keytruda, and Bristol's Opdivo, act on immune-system cells to prevent tumors from using PD-L1 to shut down an immune-system attack, and it does the trick. In the study that led to the label expansion, Keytruda alone reduced these patients' risk of disease progression or death by 50% compared with standard chemotherapies.

Image source: Getty Images.

Lung cancers claim more lives than breast, colon, and prostate cancer combined, so it isn't surprising that the FDA sped up the review process in light of those results. This is a huge win for Merck, and for lung cancer patients, because it makes Keytruda the first chemo-free treatment option for those newly diagnosed with this form of the deadly disease -- but how long it will have the field to itself is hard to pin down.

Big trouble from Basel

Roche's Tecentriq blocks the same pathway as Bristol's Opdivo and Merck's Keytruda, but instead of attaching to immune cells, it binds to PD-L1 on the surface of tumor cells. It was the third inhibitor of this checkpoint to earn an FDA approval, but it's making quick strides. Earlier this month, the agency approved the immunotherapy for treatment of certain lung cancer patients who progressed during or after platinum-based chemotherapy, just five months after granting its first approval in bladder cancer.

With seven ongoing trials testing Tecentriq in the first-line lung cancer setting, the Swiss oncology giant's differentiated immunotherapy could join Keytruda as a chemo-free treatment option for newly diagnosed patients. Merck investors will want to keep an eye on Tecentriq's progress here, as it appears effective for lung cancer patients regardless of PD-L1 expression levels. Remember, Keytruda's first-line approval is limited to patients with tumors that overexpress the protein. 

Gaining approval for patients regardless of their tumors' PD-L1 levels is more significant than you might think. Last October, the FDA granted approval to Opdivo and Keytruda for patients who progressed on or after chemotherapy, with one big difference: Oncologists don't need to test tumors for PD-L1 expression to treat their patients with Opdivo.

In the numbers

A one-size-fits-all advantage in second-line lung cancer has been been largely responsible for the wide chasm between the two drugs' sales figures. In the second quarter, Bristol-Myers Squibb recorded Opdivo sales of $840 million. More recently, Merck's third-quarter Keytruda sales were just $356 million.

Opdivo's dismal performance as a monotherapy in first-line advanced non-small-cell lung cancer -- with tumors expressing moderate levels of PD-L1 -- should allow Keytruda to maintain its advantage for at least several quarters as a chemo-free first treatment option in patients with tumors that express high levels of the protein.

Image source: Getty Images.

Keytruda's future looks brighter than it did a few months ago, but its growth alone might not be sufficient to push total sales above the peaks reached several years ago. The immunotherapy's annual run rate of $1.4 billion based on third-quarter sales should pop after the recent approval. If Roche's Tecentriq doesn't muscle into its lung cancer position, Keytruda sales could eventually top $8 billion.

Hitting such a bullish estimate would send a smaller company's top line soaring, but Merck is carrying too much weight. The Januvia franchise, which comprised 15.5% of the company's total sales in first three quarters of the year, is at a standstill and in danger of losing ground to next-generation diabetes treatments. With its biggest seller at a tipping point, and half a dozen key products falling by double digits, pulling Merck's total sales to new heights will probably require more power than any single drug can provide.

Cory Renauer has no position in any stocks mentioned. You can follow Cory on Twitter, @TMFang4apples, or LinkedIn for more healthcare industry insight.

The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.